SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma to manufacture, supply long-acting HIV treatment cabotegravir across 133 countries

15 Jul 2025 Evaluate

Aurobindo Pharma is planning to manufacture and supply the long-acting injectable HIV treatment cabotegravir across 133 countries. The company has been selected as one of the generic manufacturers under the expanded voluntary licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare.

The agreement allows Aurobindo to manufacture and supply the long-acting injectable HIV treatment across 133 countries, including several low and middle-income markets (LMICs). This update now includes long-acting cabotegravir (CAB LA) for HIV treatment, in addition to its earlier use for prevention only. The treatment offers an alternative to daily pills, allowing patients to receive just one injection every one or two months. This is a significant and timely step towards increasing access to advanced long-acting treatment in LMICs. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1416.50 -19.40 (-1.35%)
24-Apr-2026 15:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1618.50
Dr. Reddys Lab 1312.40
Cipla 1295.00
Zydus Lifesciences 930.00
Lupin 2285.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×